Iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of ICLUSIG (ponatinib) tablets brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the ICLUSIG (ponatinib) tablets medicine cost price in India.
The order for ICLUSIG (ponatinib) tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Ponatinib is used in adults to treat a type of blood cancer called chronic myeloid leukemia (CML), or Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Ponatinib is usually given after other treatments have failed.
ICLUSIG® (ponatinib) tablets for oral use Initial U.S. Approval: 2012
Generic Name: ponatinib
Tablets: 15 mg and 45 mg.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand ICLUSIG (ponatinib) tablets on prescription and Import License in Patient's Name only.
For overseas patients, ICLUSIG (ponatinib) tablets can be made available in Send your enquiry to find ICLUSIG (ponatinib) tablets in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For ICLUSIG (ponatinib) tablets Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
ARIAD Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial For More Details
Four Approved Frontline Treatments Benefit Patients with Chronic Myeloid Leukemia For More Details